Dec 3 (Reuters) - AstraZeneca has signed a deal worth up to $247 million with U.S. firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. (Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,293 GBX | -0.57% | +1.05% | +16.04% |
03:38pm | Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030 | |
01:42pm | Stifel Raises AstraZeneca PT, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,297 GBX | -0.54% | +1.05% | 244B | ||
4.895 USD | +2.19% | +0.31% | 542M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.04% | 244B | |
+36.67% | 723B | |
+31.03% | 598B | |
-3.21% | 364B | |
+20.09% | 331B | |
+4.09% | 288B | |
+9.76% | 210B | |
-5.03% | 208B | |
+9.05% | 169B | |
-0.87% | 162B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca ties up with AI biologics company to develop cancer drug - FT